U.S. Markets closed

Rosetta Genomics Ltd. (ROSG)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.43-0.06 (-3.76%)
At close: 4:00PM EDT

1.44 +0.01 (0.70%)
After hours: 6:26PM EDT

People also watch
RXIIPSTICLSNOPXACYCC
  • J
    Jake
    Jake
    Pump and dump with NO product to sell! I know what I am talking about here! Get out while you can!
  • J
    Jason
    Jason

    I will clear this up for you. $ROSG is an Israeli company. They file earnings TWICE yearly, as per their foreign-based reporting requirements. Once at end of March, once at end of September. Earnings will be out next week. I expect very solid Reveal sales. In next week's semi-annual report I expect Kenny will update us on patent developments. There have been a number of them. fully diluted share count is under 7M shares. Fully diluted MC is less than $10M. They will do more than $10M this year in revenues. Reveal revenues expected to increase from $800k last year to $4,000,000+ this year. That is crazy growth. Reveal could challenge $VCYT indeterminate thyroid nodule test Afirma, which does $16,000,000 in revenues per quarter, or $64,000,000 a year. ROSG has nearly no debt, MC of less than $10M fully diluted, growing revenues north of $10M annually, just increased its cash position, and could be cash flow positive easily by next year, with growing Reveal sales. Plus has a treasure trove of patents for using microRNA sequencing as a diagnostic for all sorts of indications (thyroid, gastric, ovarian, even Alzheimers patent pending). Finally, they appear to have reached agreement with Clinical Pathology Laboratories https://www.cpllabs.com/ to use Reveal indeterminate thyroid test exclusively in their network of hundreds of physicians.

  • L
    Littleguy
    Littleguy
    We have volume and share price climbing. Still not to the $1.70 secondary price, but up is good.
  • J
    Jake
    Jake
    Just FYI but CFO was the CFO of Toys R US! Just look what happened to them! Busted Pedro!
  • G
    Guerilla Trades
    Guerilla Trades
    Strong buying here. Long!
  • m
    michael
    michael
    so. no .bews seeking alpha lied..but 3m volume could spell then end
  • m
    michael
    michael
    ha what a sham. shabby at its best
  • m
    michael
    michael
    this must be the end. 550 shares. now we break a dollar
  • G
    Guerilla Trades
    Guerilla Trades
    long again here.
  • h
    hqpwwkwr
    hqpwwkwr

    The dork has improved my trading times 10. See for yourself at https://greatprofit12.blogspot.com/

    Penny Stocks
    greatprofit12.blogspot.com
  • m
    michael
    michael
    they only raised 4million dollars. will dilute again.or done
  • J
    Justin
    Justin
    woah volume
  • L
    Littleguy
    Littleguy
    $4 million market cap. Perhaps they should buy a McD's franchise with the $4 million. At least there would be revenue
  • L
    Littleguy
    Littleguy
    Well, look at that! Even those folks who bought the last secondary at $1.70 are down 20%. Of course they sold right away and just hung onto the options. All upside, no downside.
  • L
    Littleguy
    Littleguy
    Anyone understand the need to authorize more shares and increase the shares in the employee incentive plan? Prospectus doesn't say a thing.
  • m
    michael
    michael
    what a joke...patents?? cant afford to pay employees. think they can afford to defend patents....why make these comical announcement
  • v
    vj
    vj
    Purchase price of PDX was 12 millions ( but 10 million was worthless stocks - The purchase price includes $2.0 million in cash, 500,000 ordinary shares of Rosetta Genomics Ltd., ) So if Mr. Berlin not lying then 2.9 million is not bad a deal.
  • v
    vj
    vj
    just like 2015 and 2016 -
    We have seen an uptick in demand for Reveal primarily due to the ease-of-use of Reveal -Mr Berlin in patent press release.
  • L
    Littleguy
    Littleguy
    $4 million market cap. Last I read, Berlin was being paid $500k annually. 12% of market cap? If he owned the company outright, he wouldn't pay himself this much.